NeurogesX, Inc., a biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The company's lead product includes Qutenza (capsaicin) 8% patch, a non-narcotic analgesic formulated dermal delivery system containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and, with the aid of penetration enhancers, penetrates into the skin during application without significant absorption of capsaicin into the bloodstream. Its Qutenza has been approved by the U.S, Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia; and approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. The company's early stage product pipeline includes NGX-1998, a topical liquid formulation of capsaicin for potential use in neuropathic pain conditions; NGX-1576, NGX-9674, and NGX-5752 prodrugs of acetaminophen for potential use in acute pain, including traumatic pain, post-surgical pain, and fever; and NGX-6052, an opioid prodrug for potential use in chronic pain indications. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.